In our latest Liberty Update, we highlight how Americans have soured on "Bidenomics" despite Biden supporters…
CFIF on Twitter CFIF on YouTube
Image of the Day: Minorities Prospered Far More Under Trump

In our latest Liberty Update, we highlight how Americans have soured on "Bidenomics" despite Biden supporters' ongoing insistence that voters trust them rather than over three years of actual, real-life experience and hardship.  Well, our friends at the Committee to Unleash Prosperity have highlighted another point that merits emphasis as minorities turn against Biden in his reelection effort.  Namely, they prospered far more under President Trump than President Biden:

[caption id="" align="alignleft" width="691"] Minorities Prospered Far More Under Trump Than Biden[/caption]


June 09, 2024 • 10:40 PM

Liberty Update

CFIFs latest news, commentary and alerts delivered to your inbox.
Home Press Room CFIF Urges Senate Judiciary Committee to Protect Patent Rights and Reject Drug Price Controls to Ensure Affordable and Accessible Medications
CFIF Urges Senate Judiciary Committee to Protect Patent Rights and Reject Drug Price Controls to Ensure Affordable and Accessible Medications Print
Monday, May 20 2024
United States Senate 
Committee on the Judiciary 
224 Dirksen Office Building 
Washington, D.C.  20510 

Dear Senate Committee on the Judiciary Members and Staff: 

On behalf of the Center for Individual Freedom (hereinafter “CFIF”) and over 300,000 supporters and activists across America, I write with regard to the United States Senate Committee on the Judiciary’s scheduled May 21, 2024 full committee hearing entitled “Ensuring Affordable & Accessible Medications:  Examining Competition in the Prescription Drug Market.”  

Most importantly, we urge your strongest opposition to any proposal to weaken America’s world-leading patent protection system, introduce drug price controls into the United States healthcare system, empower the federal government to directly and bureaucratically negotiate pharmaceutical prices, or allow importation of potentially dangerous drugs from foreign countries. 

Strong patent protections, which were deliberately and explicitly incorporated into the very text of Article I of our Constitution by the Founding Fathers, provide the foundation for American pharmaceutical innovation, which historically accounts for a remarkable two-thirds of all new drugs introduced to the world.  In the famous words of former patent attorney Abraham Lincoln, strong U.S. patent rights “added the fuel of interest to the fire of genius.” 

It's not coincidence that the U.S. thus accounts for as many new lifesaving pharmaceuticals as the rest of the world combined.  Rather, that’s the direct result of our strong patent protections here in the U.S., and our more market-oriented approach.  Conversely, foreign nations that engage in price control schemes or weaken patent protections inevitably suffer shortages, as even the United Nations World Health Organization (WHO) has acknowledged

Every time one country demands a lower price, it leads to lower price reference used by other countries.  Such price controls, combined with the threat of market lockout or intellectual property infringement, prevent drug companies from charging market rates for their products, while delaying the availability of new cures to patients living in countries implementing those policies. 

That dynamic has played out across the world, according to straightforward data.  Of 270 new medicines introduced in America from 2011-2018, only 52% were available to our Canadian neighbors, 41% in Australia, 48% in Japan, 53% in France, 64% in Britain and 67% in Germany.  Patients in nations that impose drug price controls and weaken patent protections simply don’t receive access to new pharmaceuticals as quickly as Americans, if they ever receive them at all. 

In seeking public policy solutions to make medications more affordable and accessible by increasing competition in the prescription drug market, this Committee should examine potential reforms in the pharmacy benefit manager (PBM) sector.  As others such as the Trade Alliance to Promote Prosperity (TAPP) have noted, PBMs remain a driver of cost and impact affordability.  Accordingly, potential reforms to increase market competition into that realm may prove fruitful in the Committee’s pursuit. 

Simply put, abandoning free-market principles and strong patent protections in favor of price controls and weaker patents will make matters worse for American consumers, not better. 

We therefore urge you in the strongest possible terms to oppose proposals that would have that effect, and instead support more market-based solutions that have proven effective not only with pharmaceuticals, but across all economic realms. Thank you very much for your attention to this important matter, and please contact me at your convenience with any questions or comments. 

Timothy Lee
Senior Vice President of Legal and Public Affairs
Related Articles :
Notable Quote   
"The FBI learned as far back as 2016 that Hunter Biden and his partners had plotted to set up a new venture in tax-friendly Liechtenstein that would be capitalized by a whopping $120 million investment from the controversial owner of the Ukrainian energy firm Burisma Holdings, according to documents obtained by Just the News that have been kept from the American public for eight years.The mega-deal…[more]
— John Solomon and Steven Richards, Just the News
Liberty Poll   

Do you believe that Attorney General Merrick Garland runs the Justice Department straight down the line, without fear or favor?